Pipeline
Turning Evidence into Impact
Our Approach
We are revisiting psychedelics through a modern lens, incorporating advances in neuroscience and clinical research with scientific and regulatory rigor to generate high-quality, evidence-based data to better understand safety, efficacy, and mechanisms of action.
Clinical Trials
6
Participants
900+
Psychiatric and Neurological Disorders
4
Research & Development Pipeline
Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action.
- Formerly known as MM120; rINN: lysergide tartrate.
- Formerly known as MM402.
- Full trial details and clinicaltrials.gov links available on https://www.definiumtx.com/clinical-trials/.
- Studies in exploration and/or planning stage.
R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine
We are forging a new era of psychiatry
We are opening new routes for brain health by harnessing the full therapeutic potential of psychedelic medicine.
DT120 ODT
DT120 orally disintegrating tablet (ODT) is our proprietary and pharmaceutically optimized formulation of lysergide (LSD) D-tartrate. DT120 ODT increases connections between areas of the brain that aren’t normally connected, enabling changes that could treat depression, anxiety, PTSD, and other health disorders.
DT402
DT402 is the R-enantiomer of MDMA (R(-)-MDMA), selected for its serotonergic properties. In preclinical studies, DT402 has shown promising prosocial effects with a potentially superior tolerability profile compared to both racemic MDMA and the S-enantiomer.1 DT402 is being developed to target the core symptoms of autism spectrum disorder, specifically addressing social communication challenges.
Be a part of what’s next
We are working to turn breakthroughs in the lab into breakthroughs in the lives of people who are most in need. By participating in a clinical trial, you may play a crucial role in improving care and developing potential new treatments that may one day change lives, including your own.
The Latest News
